These results echo those from a trial investigating the efficacy of ibrutinib monotherapy in relapsed/refractory DLBCL patients, in which patients with mutated and wild-type CD79B responded similarly to treatment [26]. Here, CD79B is linked to diffuse large B-cell lymphoma.